Hyperfine (NASDAQ:HYPR – Get Free Report) and NeurAxis (NASDAQ:NRXS – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, institutional ownership, analyst recommendations, profitability, earnings, dividends and risk.
Profitability
This table compares Hyperfine and NeurAxis’ net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
Hyperfine | -401.00% | -44.89% | -40.96% |
NeurAxis | -594.55% | N/A | -899.27% |
Institutional & Insider Ownership
15.0% of Hyperfine shares are owned by institutional investors. Comparatively, 11.8% of NeurAxis shares are owned by institutional investors. 26.5% of Hyperfine shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Earnings & Valuation
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
Hyperfine | $11.03 million | 5.35 | -$44.24 million | ($0.62) | -1.32 |
NeurAxis | $2.46 million | 8.68 | -$14.63 million | ($4.59) | -0.71 |
NeurAxis has lower revenue, but higher earnings than Hyperfine. Hyperfine is trading at a lower price-to-earnings ratio than NeurAxis, indicating that it is currently the more affordable of the two stocks.
Analyst Recommendations
This is a summary of current ratings and price targets for Hyperfine and NeurAxis, as reported by MarketBeat.
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Hyperfine | 0 | 2 | 1 | 0 | 2.33 |
NeurAxis | 0 | 0 | 1 | 0 | 3.00 |
Hyperfine currently has a consensus price target of $2.12, indicating a potential upside of 158.13%. Given Hyperfine’s higher probable upside, research analysts plainly believe Hyperfine is more favorable than NeurAxis.
Summary
Hyperfine beats NeurAxis on 7 of the 12 factors compared between the two stocks.
About Hyperfine
Hyperfine, Inc., a medical device company, provides magnetic resonance imaging (MRI) products in the United States. The company offers Swoop Portable MR imaging system, which offers portable brain neuroimaging; and support and technical assistance services. It serves ICU, comprehensive, and primary stroke accredited facilities through direct sales and distributors. Hyperfine, Inc. was founded in 2014 and is based in Guilford, Connecticut.
About NeurAxis
NeurAxis, Inc., a medical technology company, focuses on developing neuromodulation therapies to address chronic and debilitating conditions in children and adults in the United States. It offers IB-Stim, a percutaneous electrical nerve field stimulation system intended to be used in patients 11-18 years of age with functional abdominal pain associated with irritable bowel syndrome. The company sells its products to healthcare companies, including hospitals and clinics. The company was formerly known as Innovative Health Solutions, Inc. and changed its name to NeurAxis, Inc. in March 2022. The company was founded in 2011 and is headquartered in Carmel, Indiana.
Receive News & Ratings for Hyperfine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hyperfine and related companies with MarketBeat.com's FREE daily email newsletter.